RORγt逆agonists显示IL-17A的抑制和胸细胞亡之间的差距

Mia Collins1, Rikard Pehrson2, Hanna Grindebacke1

  • 1Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

PloS one
|January 17, 2025
PubMed
概括

RORγt反向激动剂在治疗像牛皮这样的Th17驱动疾病方面表现有前途. 虽然在体外和体内都有效,但需要对胸腺效应进行进一步的研究,以确保患者的安全.